On May, 8 FibroGen, Inc. (FGEN) Analysts See $-0.51 EPS

April 16, 2018 - By Richard Doty

FibroGen, Inc. (NASDAQ:FGEN)’s earnings report is expected On May, 8., Zacks reports. Analysts predict 1.92 % diference or $-0.51 from the $-0.52 EPS from 2017. Last quarter $-0.27 earnings per share was reported. Analysts predicts 88.89 % negative EPS growth this quarter. The stock decreased 1.35% or $0.65 during the last trading session, reaching $47.4.FibroGen, Inc. has volume of 276,491 shares. Since April 17, 2017 FGEN has risen 78.19% and is uptrending. FGEN outperformed the S&P500 by 66.64%.

FibroGen, Inc. (NASDAQ:FGEN) Ratings Coverage

In total 3 analysts cover FibroGen (NASDAQ:FGEN). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 3 are the (NASDAQ:FGEN)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. On Wednesday, February 28 Leerink Swann maintained FibroGen, Inc. (NASDAQ:FGEN) rating. Leerink Swann has “Buy” rating and $88.0 target. On Thursday, March 29 the stock has “Hold” rating by Mizuho. On Wednesday, October 18 the company was maintained by Stifel Nicolaus.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States.The firm is valued at $3.92 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage.Currently it has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

FibroGen, Inc. (NASDAQ:FGEN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.